458 related articles for article (PubMed ID: 33588897)
1. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
[TBL] [Abstract][Full Text] [Related]
2. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
[TBL] [Abstract][Full Text] [Related]
4. Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.
West JB; Poarch K; Lumry WR
Clin Ther; 2021 Dec; 43(12):2154-2166.e1. PubMed ID: 34879971
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study.
Li HH; Zuraw B; Longhurst HJ; Cicardi M; Bork K; Baker J; Lumry W; Bernstein J; Manning M; Levy D; Riedl MA; Feuersenger H; Prusty S; Pragst I; Machnig T; Craig T;
Allergy Asthma Clin Immunol; 2019; 15():49. PubMed ID: 31485239
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial.
Levy DS; Farkas H; Riedl MA; Hsu FI; Brooks JP; Cicardi M; Feuersenger H; Pragst I; Reshef A
Allergy Asthma Clin Immunol; 2020; 16():8. PubMed ID: 32042283
[TBL] [Abstract][Full Text] [Related]
9. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
[TBL] [Abstract][Full Text] [Related]
10. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.
Johnson F; Stenzl A; Hofauer B; Heppt H; Ebert EV; Wollenberg B; Lochbaum R; Hahn J; Greve J; Trainotti S
Clin Rev Allergy Immunol; 2023 Dec; 65(3):354-364. PubMed ID: 37914894
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks.
Lumry WR; Miller DP; Newcomer S; Fitts D; Dayno J
Allergy Asthma Proc; 2014; 35(5):371-6. PubMed ID: 25295804
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks.
Li HH; Reshef A; Baker JW; Harper JR; Relan A
Allergy Asthma Proc; 2017 Nov; 38(6):456-461. PubMed ID: 28874235
[TBL] [Abstract][Full Text] [Related]
14. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.
Reshef A; Grivcheva-Panovska V; Kessel A; Kivity S; Klimaszewska-Rembiasz M; Moldovan D; Farkas H; Gutova V; Fritz S; Relan A; Giannetti B; Magerl M
Pediatr Allergy Immunol; 2019 Aug; 30(5):562-568. PubMed ID: 30993784
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema.
Aygören-Pürsün E; Soteres DF; Nieto-Martinez SA; Christensen J; Jacobson KW; Moldovan D; Van Leerberghe A; Tang Y; Lu P; Vardi M; Schranz J; Martinez-Saguer I
Pediatr Allergy Immunol; 2019 Aug; 30(5):553-561. PubMed ID: 30968444
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.
Craig T; Feuersenger H; Pragst I; Dang J
Allergy Asthma Proc; 2022 May; 43(3):202-208. PubMed ID: 35524357
[No Abstract] [Full Text] [Related]
19. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
[TBL] [Abstract][Full Text] [Related]
20. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
